ATE419357T1 - Dna 19355 polypeptide, ein homolog des tumornekrosefaktors - Google Patents

Dna 19355 polypeptide, ein homolog des tumornekrosefaktors

Info

Publication number
ATE419357T1
ATE419357T1 AT98958067T AT98958067T ATE419357T1 AT E419357 T1 ATE419357 T1 AT E419357T1 AT 98958067 T AT98958067 T AT 98958067T AT 98958067 T AT98958067 T AT 98958067T AT E419357 T1 ATE419357 T1 AT E419357T1
Authority
AT
Austria
Prior art keywords
necrosis factor
tumor necrosis
dna19355
homologue
polypeptides
Prior art date
Application number
AT98958067T
Other languages
English (en)
Inventor
Avi Ashkenazi
Austin Gurney
Scot Marsters
Robert Pitti
Kevin Baker
Paul Godowski
Melanie Mark
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE419357T1 publication Critical patent/ATE419357T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98958067T 1997-11-18 1998-11-18 Dna 19355 polypeptide, ein homolog des tumornekrosefaktors ATE419357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6563597P 1997-11-18 1997-11-18
US6966197P 1997-12-12 1997-12-12

Publications (1)

Publication Number Publication Date
ATE419357T1 true ATE419357T1 (de) 2009-01-15

Family

ID=26745805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98958067T ATE419357T1 (de) 1997-11-18 1998-11-18 Dna 19355 polypeptide, ein homolog des tumornekrosefaktors

Country Status (12)

Country Link
US (4) US20020146389A1 (de)
EP (1) EP1032672B1 (de)
JP (2) JP4485049B2 (de)
AT (1) ATE419357T1 (de)
AU (1) AU760010B2 (de)
CA (1) CA2308365A1 (de)
DE (1) DE69840413D1 (de)
DK (1) DK1032672T3 (de)
ES (1) ES2320285T3 (de)
IL (1) IL135911A0 (de)
PT (1) PT1032672E (de)
WO (1) WO1999025834A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009327A2 (en) * 1999-07-28 2001-02-08 Genentech, Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
WO2001040464A1 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
DK1212417T3 (da) * 1999-06-02 2008-09-01 Genentech Inc Fremmelse eller inhibering af angiogenese og vaskularisering
ATE376837T1 (de) * 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
WO2003006058A1 (en) * 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
WO2003070763A1 (en) * 2001-08-16 2003-08-28 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
EP1495756A4 (de) * 2002-04-08 2009-10-28 Takeda Pharmaceutical Therapeutikum zur prävention schwerer sepsis
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
EP1660126A1 (de) * 2003-07-11 2006-05-31 Schering Corporation Agonisten oder antagonisten des glucocorticoid-induzierten tumor-nekosefaktor-rezeptors (gitr) oder seiner liganden zur behandlung von immunstörungen, infektionen und krebs
EP1692318A4 (de) * 2003-12-02 2008-04-02 Genzyme Corp Zusammensetzungen und verfahren zur diagnose und behandlung von lungenkrebs
US20070065889A1 (en) * 2004-12-02 2007-03-22 Roberts Bruce L Compositions and methods to diagnose and treat lung cancer
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3304079B1 (de) 2015-06-03 2020-06-03 Bristol-Myers Squibb Company Anti-gitr-antikörper zur krebsdiagnostik
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
MX2022010910A (es) 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
CA2225378C (en) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine that induces apoptosis
WO1998007880A1 (en) * 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Human endokine alpha
US5998171A (en) * 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use

Also Published As

Publication number Publication date
IL135911A0 (en) 2001-05-20
US20060216270A1 (en) 2006-09-28
US20040234498A1 (en) 2004-11-25
DE69840413D1 (de) 2009-02-12
CA2308365A1 (en) 1999-05-27
AU760010B2 (en) 2003-05-08
EP1032672A1 (de) 2000-09-06
DK1032672T3 (da) 2009-04-27
JP2001523459A (ja) 2001-11-27
WO1999025834A1 (en) 1999-05-27
JP2010088448A (ja) 2010-04-22
US20020146389A1 (en) 2002-10-10
JP4485049B2 (ja) 2010-06-16
EP1032672B1 (de) 2008-12-31
AU1418099A (en) 1999-06-07
PT1032672E (pt) 2009-04-02
US20070072263A1 (en) 2007-03-29
ES2320285T3 (es) 2009-05-20

Similar Documents

Publication Publication Date Title
DE69840413D1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
BG100771A (bg) Хематопоетичен протеин и материали и методи за неговото получаване
ATE393222T1 (de) Dcr3 polypeptid, ein tnfr homolog
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DE69836956D1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
ES2072892T3 (es) Proteina receptora para un factor 2 estimulante de celulas b humanas.
DE69022559D1 (de) Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
DE69535719D1 (de) Fas-antigenbindender ligand
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
DE69939330D1 (de) Wachstumsfaktor-homologe zvegf-3
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
JPS6420095A (en) Polypeptide having anti-blood coagulating action
WO2000039149A3 (en) Secreted proteins and uses thereof
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
DE59712771D1 (de) Nebenhoden-spezifisches Rezeptorprotein und dessen Verwendung
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen
KR950032620A (ko) 인터페론 α/β 결합 단백질과 이의 제조 및 용도
EA200401390A1 (ru) N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения
ATE288491T1 (de) Polypeptide mit 5-aminolevulinsäure synthaseaktivität und deren nukleinsäuren
ATE87977T1 (de) Herstellung menschlichen somatomedins c.
TR199802168T2 (xx) IL-16 Aktivitesine sahip işlenmiş polipeptidler, bunları üretmeye mahsus yöntemler ve bunların kullanımı.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1032672

Country of ref document: EP